Immunomodulation and antitumor effects of MVE-2 in mice

James E Talmadge, Annette E. Maluish, Margaret Collins, Mark Schneider, Ronald B. Herberman, Robert K. Oldham, Robert H. Wiltrout

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The biological response modifier maleic anhydride-divinyl ether (MVE-2) can activate natural killer (NK) cells and macrophages and can act as an immunoadjuvant for T and B cells. MVE-2 activates macrophages following intravenous or intraperitoneal injection in a compartmentalized manner, i.e., peritoneal macrophages (i.p. injection) or alveolar macrophages (i.v. injection). It activates NK cells in vivo but not in vitro, a dichotomy that may be secondary to interferon production. Splenic NK cell activity is not prolonged by the multiple injection of MVE-2; instead, it induces a state of NK cell hyporesponsiveness, which may limit its therapeutic efficiency. Therapeutic properties of MVE-2 are largely limited to nonspecific immunoprophylaxis, which may be associated with NK cell activation but which does not necessarily correlate with the level of splenic NK cell activation. Minimal therapeutic efficiency consisting of a slight prolongation in survival is observed in mice with preexistent disease treated with MVE-2. Prolonged survival is observed only in those animals placed on therapy soon after tumor cell challenge (experimental metastasis) and not in mice with established spontaneous metastasis. The need to manipulate the animal model (MVE-2 injection prior to or rapidly following tumor challenge) seems to predict that this agent is unlikely to be clinically useful against preexistent metastatic tumor burden, although some efficiency may be associated with local treatment into the pleural or peritoneal cavity.

Original languageEnglish (US)
Pages (from-to)634-652
Number of pages19
JournalJournal of Biological Response Modifiers
Volume3
Issue number6
StatePublished - Jan 1 1984

Fingerprint

Pyran Copolymer
Immunomodulation
Natural Killer Cells
Injections
Macrophages
Neoplasm Metastasis
Therapeutics
Immunologic Adjuvants
Pleural Cavity
Peritoneal Cavity
Alveolar Macrophages
Immunologic Factors
Peritoneal Macrophages
Tumor Burden
Intraperitoneal Injections
Intravenous Injections
Interferons
Neoplasms
B-Lymphocytes
Animal Models

Keywords

  • Immunomodulation
  • Immunotheraphy
  • MVE-2
  • Macrophage activation
  • Metastasis
  • Natural killer cells

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Talmadge, J. E., Maluish, A. E., Collins, M., Schneider, M., Herberman, R. B., Oldham, R. K., & Wiltrout, R. H. (1984). Immunomodulation and antitumor effects of MVE-2 in mice. Journal of Biological Response Modifiers, 3(6), 634-652.

Immunomodulation and antitumor effects of MVE-2 in mice. / Talmadge, James E; Maluish, Annette E.; Collins, Margaret; Schneider, Mark; Herberman, Ronald B.; Oldham, Robert K.; Wiltrout, Robert H.

In: Journal of Biological Response Modifiers, Vol. 3, No. 6, 01.01.1984, p. 634-652.

Research output: Contribution to journalArticle

Talmadge, JE, Maluish, AE, Collins, M, Schneider, M, Herberman, RB, Oldham, RK & Wiltrout, RH 1984, 'Immunomodulation and antitumor effects of MVE-2 in mice', Journal of Biological Response Modifiers, vol. 3, no. 6, pp. 634-652.
Talmadge JE, Maluish AE, Collins M, Schneider M, Herberman RB, Oldham RK et al. Immunomodulation and antitumor effects of MVE-2 in mice. Journal of Biological Response Modifiers. 1984 Jan 1;3(6):634-652.
Talmadge, James E ; Maluish, Annette E. ; Collins, Margaret ; Schneider, Mark ; Herberman, Ronald B. ; Oldham, Robert K. ; Wiltrout, Robert H. / Immunomodulation and antitumor effects of MVE-2 in mice. In: Journal of Biological Response Modifiers. 1984 ; Vol. 3, No. 6. pp. 634-652.
@article{19e2ab10c9dc4d7b86cca3350e91d49d,
title = "Immunomodulation and antitumor effects of MVE-2 in mice",
abstract = "The biological response modifier maleic anhydride-divinyl ether (MVE-2) can activate natural killer (NK) cells and macrophages and can act as an immunoadjuvant for T and B cells. MVE-2 activates macrophages following intravenous or intraperitoneal injection in a compartmentalized manner, i.e., peritoneal macrophages (i.p. injection) or alveolar macrophages (i.v. injection). It activates NK cells in vivo but not in vitro, a dichotomy that may be secondary to interferon production. Splenic NK cell activity is not prolonged by the multiple injection of MVE-2; instead, it induces a state of NK cell hyporesponsiveness, which may limit its therapeutic efficiency. Therapeutic properties of MVE-2 are largely limited to nonspecific immunoprophylaxis, which may be associated with NK cell activation but which does not necessarily correlate with the level of splenic NK cell activation. Minimal therapeutic efficiency consisting of a slight prolongation in survival is observed in mice with preexistent disease treated with MVE-2. Prolonged survival is observed only in those animals placed on therapy soon after tumor cell challenge (experimental metastasis) and not in mice with established spontaneous metastasis. The need to manipulate the animal model (MVE-2 injection prior to or rapidly following tumor challenge) seems to predict that this agent is unlikely to be clinically useful against preexistent metastatic tumor burden, although some efficiency may be associated with local treatment into the pleural or peritoneal cavity.",
keywords = "Immunomodulation, Immunotheraphy, MVE-2, Macrophage activation, Metastasis, Natural killer cells",
author = "Talmadge, {James E} and Maluish, {Annette E.} and Margaret Collins and Mark Schneider and Herberman, {Ronald B.} and Oldham, {Robert K.} and Wiltrout, {Robert H.}",
year = "1984",
month = "1",
day = "1",
language = "English (US)",
volume = "3",
pages = "634--652",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Immunomodulation and antitumor effects of MVE-2 in mice

AU - Talmadge, James E

AU - Maluish, Annette E.

AU - Collins, Margaret

AU - Schneider, Mark

AU - Herberman, Ronald B.

AU - Oldham, Robert K.

AU - Wiltrout, Robert H.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The biological response modifier maleic anhydride-divinyl ether (MVE-2) can activate natural killer (NK) cells and macrophages and can act as an immunoadjuvant for T and B cells. MVE-2 activates macrophages following intravenous or intraperitoneal injection in a compartmentalized manner, i.e., peritoneal macrophages (i.p. injection) or alveolar macrophages (i.v. injection). It activates NK cells in vivo but not in vitro, a dichotomy that may be secondary to interferon production. Splenic NK cell activity is not prolonged by the multiple injection of MVE-2; instead, it induces a state of NK cell hyporesponsiveness, which may limit its therapeutic efficiency. Therapeutic properties of MVE-2 are largely limited to nonspecific immunoprophylaxis, which may be associated with NK cell activation but which does not necessarily correlate with the level of splenic NK cell activation. Minimal therapeutic efficiency consisting of a slight prolongation in survival is observed in mice with preexistent disease treated with MVE-2. Prolonged survival is observed only in those animals placed on therapy soon after tumor cell challenge (experimental metastasis) and not in mice with established spontaneous metastasis. The need to manipulate the animal model (MVE-2 injection prior to or rapidly following tumor challenge) seems to predict that this agent is unlikely to be clinically useful against preexistent metastatic tumor burden, although some efficiency may be associated with local treatment into the pleural or peritoneal cavity.

AB - The biological response modifier maleic anhydride-divinyl ether (MVE-2) can activate natural killer (NK) cells and macrophages and can act as an immunoadjuvant for T and B cells. MVE-2 activates macrophages following intravenous or intraperitoneal injection in a compartmentalized manner, i.e., peritoneal macrophages (i.p. injection) or alveolar macrophages (i.v. injection). It activates NK cells in vivo but not in vitro, a dichotomy that may be secondary to interferon production. Splenic NK cell activity is not prolonged by the multiple injection of MVE-2; instead, it induces a state of NK cell hyporesponsiveness, which may limit its therapeutic efficiency. Therapeutic properties of MVE-2 are largely limited to nonspecific immunoprophylaxis, which may be associated with NK cell activation but which does not necessarily correlate with the level of splenic NK cell activation. Minimal therapeutic efficiency consisting of a slight prolongation in survival is observed in mice with preexistent disease treated with MVE-2. Prolonged survival is observed only in those animals placed on therapy soon after tumor cell challenge (experimental metastasis) and not in mice with established spontaneous metastasis. The need to manipulate the animal model (MVE-2 injection prior to or rapidly following tumor challenge) seems to predict that this agent is unlikely to be clinically useful against preexistent metastatic tumor burden, although some efficiency may be associated with local treatment into the pleural or peritoneal cavity.

KW - Immunomodulation

KW - Immunotheraphy

KW - MVE-2

KW - Macrophage activation

KW - Metastasis

KW - Natural killer cells

UR - http://www.scopus.com/inward/record.url?scp=0021746059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021746059&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 634

EP - 652

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -